Literature DB >> 32932518

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.

Paolo Strati1, Preetesh Jain1, Ralph J Johnson1, Sheryl Forbes1, Lei Feng2, Felipe Samaniego1, Maria A Rodriguez1, Luis E Fayad1, Fredrick Hagemeister1, Jason Westin1, Michael Wang1, Sattva S Neelapu1, Loretta J Nastoupil1, Nathan H Fowler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 32932518      PMCID： PMC7907727          DOI： 10.1182/blood.2020007994

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  24 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Authors:  Nathan H Fowler; R Eric Davis; Seema Rawal; Loretta Nastoupil; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle A Fanale; Luis E Fayad; Jason R Westin; Jatin Shah; Robert Z Orlowski; Michael Wang; Francesco Turturro; Yasuhiro Oki; Linda C Claret; Lei Feng; Veerabhadran Baladandayuthapani; Tariq Muzzafar; Kenneth Y Tsai; Felipe Samaniego; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

3.  Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy.

Authors:  Thomas Menter; Alexandar Tzankov; Emanuele Zucca; Eva Kimby; Magnus Hultdin; Christer Sundström; Klaus Beiske; Sergio Cogliatti; Yara Banz; Gieri Cathomas; Marja-Liisa Karjalainen-Lindsberg; Rainer Grobholz; Luca Mazzucchelli; Birgitta Sander; Hanne Hawle; Stefanie Hayoz; Stefan Dirnhofer
Journal:  Br J Haematol       Date:  2020-02-03       Impact factor: 6.998

4.  The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).

Authors:  S Luminari; I Biasoli; A Versari; S Rattotti; C Bottelli; C Rusconi; F Merli; M Spina; A J M Ferreri; P L Zinzani; A Gallamini; A Franceschetto; C Boccomini; S Franceschetti; F Salvi; F D Raimondo; A M Carella; Q Micol; M Balzarotti; P Musto; M Federico
Journal:  Ann Oncol       Date:  2014-01-10       Impact factor: 32.976

5.  Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

Authors:  Judith Trotman; Marion Fournier; Thierry Lamy; John Francis Seymour; Anne Sonet; Andrea Janikova; Ofer Shpilberg; Emmanuel Gyan; Hervé Tilly; Jane Estell; Cecily Forsyth; Didier Decaudin; Bettina Fabiani; Jean Gabarre; Bruno Salles; Eric Van Den Neste; Danielle Canioni; Etienne Garin; Michael Fulham; Thierry Vander Borght; Gilles Salles
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

6.  First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad Kahl; Peter Wood; Tim Hawkins; David MacDonald; David Simpson; Kathryn Kolibaba; Samar Issa; Julie Chang; Judith Trotman; Doreen Hallman; Ling Chen; John M Burke
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

7.  Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

Authors:  Clémentine Sarkozy; Matthew J Maurer; Brian K Link; Hervé Ghesquieres; Emmanuelle Nicolas; Carrie A Thompson; Alexandra Traverse-Glehen; Andrew L Feldman; Cristine Allmer; Susan L Slager; Stephen M Ansell; Thomas M Habermann; Emmanuel Bachy; James R Cerhan; Gilles Salles
Journal:  J Clin Oncol       Date:  2018-11-27       Impact factor: 44.544

8.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

Authors:  Massimo Federico; Monica Bellei; Luigi Marcheselli; Stefano Luminari; Armando Lopez-Guillermo; Umberto Vitolo; Barbara Pro; Stefano Pileri; Alessandro Pulsoni; Pierre Soubeyran; Sergio Cortelazzo; Giovanni Martinelli; Maurizio Martelli; Luigi Rigacci; Luca Arcaini; Francesco Di Raimondo; Francesco Merli; Elena Sabattini; Peter McLaughlin; Philippe Solal-Céligny
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

9.  Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.

Authors:  Paolo Strati; Mohamed Amin Ahmed; Nathan H Fowler; Loretta J Nastoupil; Felipe Samaniego; Luis E Fayad; Fredrick B Hagemeister; Jorge E Romaguera; Alma Rodriguez; Michael Wang; Jason R Westin; Chan Cheah; Mansoor Noorani; Lei Feng; Richard E Davis; Sattva S Neelapu
Journal:  Haematologica       Date:  2019-10-10       Impact factor: 9.941

10.  Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Authors:  Hsiling Chiu; Preeti Trisal; Chad Bjorklund; Soraya Carrancio; Estela G Toraño; Carla Guarinos; Despoina Papazoglou; Patrick R Hagner; Asma Beldi-Ferchiou; Karin Tarte; Marie-Hélène Delfau-Larue; Franck Morschhauser; Alan G Ramsay; Anita K Gandhi
Journal:  Br J Haematol       Date:  2019-02-14       Impact factor: 6.998
View more
  3 in total

1.  SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.

Authors:  Mario L Marques-Piubelli; Edwin R Parra; Lei Feng; Luisa Solis Soto; Mariana Gallardo; Sushanth Gouni; Felipe Samaniego; Mansoor Noorani; Fredrick B Hagemeister; Jason R Westin; Hun Ju Lee; Maria A Rodriguez; Sattva S Neelapu; Jillian R Gunther; Nathan H Fowler; Christopher R Flowers; Ignacio I Wistuba; Loretta J Nastoupil; Francisco Vega; Paolo Strati
Journal:  Blood Adv       Date:  2022-06-14

Review 2.  An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date.

Authors:  Umut Yilmaz; Ayse Salihoglu; Teoman Soysal
Journal:  Drug Des Devel Ther       Date:  2021-09-07       Impact factor: 4.162

3.  Follicular lymphoma and macrophages: impact of approved and novel therapies.

Authors:  Sushanth Gouni; Mario L Marques-Piubelli; Paolo Strati
Journal:  Blood Adv       Date:  2021-10-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.